Cincinnati Moeller junior quarterback Matt Ponatoski was named Ohio Mr. Football by the Ohio Prep Sports Media Association on Dec. 5. Ponatoski is the 38th winner of the award and the second in a row for Moeller. Running back Jordan Marshall won the award last year. Ponatoski, 6-foot-1 and 195 pounds, totaled 70 points in the statewide voting by OPSMA members. He will lead Moeller into the Division I state championship game against Olentangy Liberty on Dec. 6 at Tom Benson Hall of Fame Stadium in Canton. Last month, Ponatoski was named Southwest District Division I Offensive Player of the [...]jackpot 777 jogo 。

Clintons urge voters agitated by today's politics to remain involved in public service

TimAbramowitz GigaCloud Is Discounted For Good Reasons - Reiterate Hold We previously covered GigaCloud Technology Inc. (NASDAQ: GCT ) in August 2024, discussing its significant volatility after the short attacks , along with the market rotation from high Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.U.S. court tosses hostile workplace, pay discrimination claims against BlackBerry

Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. ("Pharming" or "the Company") PHAR today announced a recommended public cash offer to the shareholders of Abliva AB ("Abliva") to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V., offers the shareholders SEK 0.45 in cash per share in Abliva. The transaction is valued at approximately US$66.1 million. Abliva is a biotechnology company, based in Lund, Sweden, focused on developing medicines for the treatment of mitochondrial disease. Abliva's lead product, KL1333, a regulator of the essential co-enzymes NAD+ and NADH, is in a pivotal clinical study (FALCON) in adult patients with genetically confirmed primary mitochondrial disease (PMD) with mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy), and reduced life expectancy. Over 30,000 patients diagnosed with mtDNA mitochondrial disease would be potentially addressable by KL1333 in the U.S., EU4 (France, Germany, Italy, Spain) and the UK. KL1333 has shown positive clinical effects in a proof-of-concept Phase 1b study, and a pre-planned interim analysis of the ongoing pivotal FALCON trial demonstrated promising differences over placebo in both alternate primary efficacy endpoints. KL1333 has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of PMD in the U.S. and EU. Sijmen de Vries, Chief Executive Officer of Pharming, said: "Abliva has made exciting progress developing KL1333, a potential first-in-disease treatment undergoing a pivotal clinical trial that offers new hope to patients with rare mtDNA mitochondrial disease who experience debilitating fatigue and muscle weakness. With over 30,000 addressable patients in the U.S., EU4 and UK, we are excited about the potential of this asset, which achieved a positive interim analysis in the registration trial in July 2024. We believe KL1333 has blockbuster potential in the U.S. alone and can significantly change Pharming's future growth trajectory. We will fund this acquisition using existing cash, and anticipate covering costs to complete the pivotal trial with positive cash flows from our existing business. The acquisition of Abliva would further strengthen our clinical pipeline with the addition of a therapy, with U.S. launch expected in 2028, aligning with our vision to become a leading global rare disease company. We are pleased that Abliva's independent Board of Directors and major shareholders recognize the expertise and value Pharming brings to the development and eventual commercialization of KL1333, and unanimously support this transaction. We look forward to welcoming the Abliva team with their strong expertise in mitochondrial research and drug development and to combining with our resources, capabilities and commercial infrastructure to bring this groundbreaking and important medicine to patients and their healthcare providers." Transaction highlights Today at 19:45 CET, Pharming announced a recommended cash offer to the shareholders of Abliva AB. Hereby Pharming, through a wholly owned subsidiary, has offered SEK 0.45 in cash for each outstanding share of Abliva (the ''Offer''). The total value of the Offer based on all outstanding 1,611,884,536 shares in Abliva amounts to approximately SEK 725,348,041, or approximately US$66.1 million. The Board of Directors of Abliva unanimously recommends the shareholders of Abliva to accept the Offer. The Board of Directors of Abliva has obtained a fairness opinion from PwC, according to which, based on the assumptions and reservations stated in the opinion, the Offer is fair to Abliva's shareholders from a financial perspective. Pharming has obtained acceptance undertakings from the three largest shareholders, accounting for 49.82% of Abliva's outstanding shares. The Offer is subject to customary regulatory approvals, and Pharming expects to obtain such approvals prior to the end of the acceptance period. Pharming Group N.V. has cash on hand to finance the Offer in full. The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025. For information in relation to the Offer, please refer to www.raredisease-offer.com . An offer document will be made public by Pharming shortly before the commencement of the acceptance period. Van Lanschot Kempen N.V. is sole financial advisor and NautaDutilh N.V. and Mannheimer Swartling Advokatbyrå are legal advisors to Pharming in connection with the Offer. Invitation to conference call Pharming to host a conference call on Monday, December 16, 2024, at 14:00 CET (8:00 am EST). The conference call presentation is available on the pharming.com website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming.com website in the days following the call. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call dial-in details: Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BIfcd1fd2bdf0e443cbf6192dc063763ad Webcast Link: https://edge.media-server.com/mmc/p/2hfpccyi For further public information, contact: Pharming Group, Leiden, the Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com FTI Consulting, London, UK Victoria Foster Mitchell/Alex Shaw/Amy Byrne T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 53 81 64 27 E: pharming@lifespring.nl Abliva investors Leo Wei T: +46 (0)709 910 081 E: pharming@fogelpartners.se About KL1333 KL1333 has been designed to treat chronic fatigue and myopathy (muscle weakness) in genetically confirmed adult patients with primary mitochondrial disease. Diagnoses can include MELAS-MIDD and KSS-CPEO spectrum disorders as well as MERRF syndrome. The drug candidate is intended for long-term oral treatment. KL1333 has the ability to restore the ratio of NAD+ and NADH, and thus leads to the formation of new mitochondria and improved energy levels. In a cohort of mitochondrial disease patients in a Phase 1a/b study, the patients who received KL1333 showed both improvements in symptoms of fatigue as well as functional improvements. KL1333 is currently being evaluated in a global, potentially registrational, Phase 2 study (the FALCON study) and has received orphan drug designation in both the USA and Europe as well as Fast Track designation in the USA. About the FALCON Study FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational study evaluating the safety and efficacy of KL1333 in adult patients with primary mitochondrial disease who experience consistent, debilitating fatigue and myopathy (muscle weakness), the most common and impairing symptoms. A total of 180 patients with mitochondrial DNA mutations who meet the eligibility criteria are randomized 3:2 to receive KL1333 (50mg-100mg) or placebo twice daily for 48 weeks. The two alternative primary endpoints assess consistent fatigue (using the PROMIS® Fatigue Mitochondrial Disease Short Form) and myopathy (using the 30 second Sit-to-Stand test), only one of which must be positive to file for marketing approval. An interim analysis evaluating 24-week data from the first wave of patients confirmed the strong safety profile of KL1333, and both primary endpoints passed futility, meaning that both have the potential to demonstrate benefit in the final analysis of the study. About Abliva AB Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD+ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden ABLI . For more information, please visit www.abliva.com. About Pharming Group N.V. Pharming Group N.V. PHAR is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", ‘‘anticipate'', ‘‘believe'', ‘‘could'', ‘‘estimate'', ‘‘expect'', ‘‘goals'', ‘‘intend'', ‘‘may'', "milestones", ‘‘objectives'', ‘‘outlook'', ‘‘plan'', ‘‘probably'', ‘‘project'', ‘‘risks'', "schedule", ‘‘seek'', ‘‘should'', ‘‘target'', ‘‘will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Attachment Pharming announces public cash offer to the shareholders of Abliva AB_EN_15DEC24 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. ("Pharming" or "the Company") PHAR today announced a recommended public cash offer to the shareholders of Abliva AB ("Abliva") to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V., offers the shareholders SEK 0.45 in cash per share in Abliva. The transaction is valued at approximately US$66.1 million. Abliva is a biotechnology company, based in Lund, Sweden, focused on developing medicines for the treatment of mitochondrial disease. Abliva's lead product, KL1333, a regulator of the essential co-enzymes NAD+ and NADH, is in a pivotal clinical study (FALCON) in adult patients with genetically confirmed primary mitochondrial disease (PMD) with mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy), and reduced life expectancy. Over 30,000 patients diagnosed with mtDNA mitochondrial disease would be potentially addressable by KL1333 in the U.S., EU4 (France, Germany, Italy, Spain) and the UK. KL1333 has shown positive clinical effects in a proof-of-concept Phase 1b study, and a pre-planned interim analysis of the ongoing pivotal FALCON trial demonstrated promising differences over placebo in both alternate primary efficacy endpoints. KL1333 has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of PMD in the U.S. and EU. Sijmen de Vries, Chief Executive Officer of Pharming, said: "Abliva has made exciting progress developing KL1333, a potential first-in-disease treatment undergoing a pivotal clinical trial that offers new hope to patients with rare mtDNA mitochondrial disease who experience debilitating fatigue and muscle weakness. With over 30,000 addressable patients in the U.S., EU4 and UK, we are excited about the potential of this asset, which achieved a positive interim analysis in the registration trial in July 2024. We believe KL1333 has blockbuster potential in the U.S. alone and can significantly change Pharming's future growth trajectory. We will fund this acquisition using existing cash, and anticipate covering costs to complete the pivotal trial with positive cash flows from our existing business. The acquisition of Abliva would further strengthen our clinical pipeline with the addition of a therapy, with U.S. launch expected in 2028, aligning with our vision to become a leading global rare disease company. We are pleased that Abliva's independent Board of Directors and major shareholders recognize the expertise and value Pharming brings to the development and eventual commercialization of KL1333, and unanimously support this transaction. We look forward to welcoming the Abliva team with their strong expertise in mitochondrial research and drug development and to combining with our resources, capabilities and commercial infrastructure to bring this groundbreaking and important medicine to patients and their healthcare providers." Transaction highlights Today at 19:45 CET, Pharming announced a recommended cash offer to the shareholders of Abliva AB. Hereby Pharming, through a wholly owned subsidiary, has offered SEK 0.45 in cash for each outstanding share of Abliva (the ''Offer''). The total value of the Offer based on all outstanding 1,611,884,536 shares in Abliva amounts to approximately SEK 725,348,041, or approximately US$66.1 million. The Board of Directors of Abliva unanimously recommends the shareholders of Abliva to accept the Offer. The Board of Directors of Abliva has obtained a fairness opinion from PwC, according to which, based on the assumptions and reservations stated in the opinion, the Offer is fair to Abliva's shareholders from a financial perspective. Pharming has obtained acceptance undertakings from the three largest shareholders, accounting for 49.82% of Abliva's outstanding shares. The Offer is subject to customary regulatory approvals, and Pharming expects to obtain such approvals prior to the end of the acceptance period. Pharming Group N.V. has cash on hand to finance the Offer in full. The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025. For information in relation to the Offer, please refer to www.raredisease-offer.com . An offer document will be made public by Pharming shortly before the commencement of the acceptance period. Van Lanschot Kempen N.V. is sole financial advisor and NautaDutilh N.V. and Mannheimer Swartling Advokatbyrå are legal advisors to Pharming in connection with the Offer. Invitation to conference call Pharming to host a conference call on Monday, December 16, 2024, at 14:00 CET (8:00 am EST). The conference call presentation is available on the pharming.com website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming.com website in the days following the call. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call dial-in details: Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BIfcd1fd2bdf0e443cbf6192dc063763ad Webcast Link: https://edge.media-server.com/mmc/p/2hfpccyi For further public information, contact: Pharming Group, Leiden, the Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com FTI Consulting, London, UK Victoria Foster Mitchell/Alex Shaw/Amy Byrne T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 53 81 64 27 E: pharming@lifespring.nl Abliva investors Leo Wei T: +46 (0)709 910 081 E: pharming@fogelpartners.se About KL1333 KL1333 has been designed to treat chronic fatigue and myopathy (muscle weakness) in genetically confirmed adult patients with primary mitochondrial disease. Diagnoses can include MELAS-MIDD and KSS-CPEO spectrum disorders as well as MERRF syndrome. The drug candidate is intended for long-term oral treatment. KL1333 has the ability to restore the ratio of NAD+ and NADH, and thus leads to the formation of new mitochondria and improved energy levels. In a cohort of mitochondrial disease patients in a Phase 1a/b study, the patients who received KL1333 showed both improvements in symptoms of fatigue as well as functional improvements. KL1333 is currently being evaluated in a global, potentially registrational, Phase 2 study (the FALCON study) and has received orphan drug designation in both the USA and Europe as well as Fast Track designation in the USA. About the FALCON Study FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational study evaluating the safety and efficacy of KL1333 in adult patients with primary mitochondrial disease who experience consistent, debilitating fatigue and myopathy (muscle weakness), the most common and impairing symptoms. A total of 180 patients with mitochondrial DNA mutations who meet the eligibility criteria are randomized 3:2 to receive KL1333 (50mg-100mg) or placebo twice daily for 48 weeks. The two alternative primary endpoints assess consistent fatigue (using the PROMIS® Fatigue Mitochondrial Disease Short Form) and myopathy (using the 30 second Sit-to-Stand test), only one of which must be positive to file for marketing approval. An interim analysis evaluating 24-week data from the first wave of patients confirmed the strong safety profile of KL1333, and both primary endpoints passed futility, meaning that both have the potential to demonstrate benefit in the final analysis of the study. About Abliva AB Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD+ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden ABLI . For more information, please visit www.abliva.com. About Pharming Group N.V. Pharming Group N.V. PHAR is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", ‘‘anticipate'', ‘‘believe'', ‘‘could'', ‘‘estimate'', ‘‘expect'', ‘‘goals'', ‘‘intend'', ‘‘may'', "milestones", ‘‘objectives'', ‘‘outlook'', ‘‘plan'', ‘‘probably'', ‘‘project'', ‘‘risks'', "schedule", ‘‘seek'', ‘‘should'', ‘‘target'', ‘‘will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Attachment Pharming announces public cash offer to the shareholders of Abliva AB_EN_15DEC24 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.None

Ovarian Hyperstimulation Treatment Market: Trends, Size, Share, Growth, and Demand by 2030 12-05-2024 09:02 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research (DBMR) Ovarian Hyperstimulation Treatment Market The ovarian hyperstimulation treatment market is gaining significant traction worldwide due to its pivotal role in addressing infertility. Ovarian hyperstimulation involves hormonal therapy to stimulate the ovaries to produce multiple eggs for procedures such as in vitro fertilization (IVF). As infertility rates rise globally, driven by factors like delayed parenthood, lifestyle changes, and medical conditions, the demand for innovative ovarian hyperstimulation treatments has surged. This article delves into the trends, market size, share, growth potential, and anticipated demand in the ovarian hyperstimulation treatment market by 2030. Access Full 350-page PDF Report @ https://www.databridgemarketresearch.com/reports/global-ovarian-hyperstimulation-treatment-market Trends in Ovarian Hyperstimulation Treatment Technological Advancements in Fertility Treatment Continuous innovation in medical technology has significantly enhanced the efficacy and safety of ovarian hyperstimulation treatments. Developments such as advanced hormone therapy drugs, precise diagnostic tools, and personalized treatment plans are shaping the market's future. Rising Preference for Assisted Reproductive Technologies (ART) With increasing awareness about ART and its success rates, more individuals are opting for procedures like IVF. Ovarian hyperstimulation plays a critical role in these procedures, thereby boosting its demand. Focus on Minimizing Risks Efforts to reduce complications like ovarian hyperstimulation syndrome (OHSS) have led to the development of safer treatment protocols and drugs. This has increased patient confidence in these treatments. Growth of Fertility Clinics and Specialized Centers The proliferation of fertility clinics and dedicated reproductive health centers worldwide has made ovarian hyperstimulation treatments more accessible. Many of these clinics offer comprehensive fertility services, including consultations, diagnostics, and advanced treatments. Shift Toward Eco-Friendly and Ethical Practices In response to environmental concerns and ethical considerations, many companies are focusing on sustainable manufacturing practices for hormone therapy drugs. Additionally, there is an emphasis on ensuring equitable access to fertility treatments. Market Size Data Bridge Market Research analyses a growth rate in the ovarian hyperstimulation treatment market in the forecast period 2023-2030. The expected CAGR of ovarian hyperstimulation treatment market is around 5% in the mentioned forecast period. The market was valued at USD 5.7 billion in 2022, and it would grow upto USD 8.42 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. Market Share The market is characterized by the dominance of key players, including pharmaceutical companies, fertility clinics, and medical device manufacturers. Geographically, North America holds the largest market share, driven by high awareness levels, advanced healthcare infrastructure, and supportive government policies. Europe follows closely, with countries like the UK, Germany, and France contributing significantly. The Asia-Pacific region is emerging as a lucrative market due to rising awareness, improving healthcare infrastructure, and growing medical tourism. Growth Drivers Increasing Infertility Rates The global rise in infertility rates is one of the primary drivers of the ovarian hyperstimulation treatment market. Factors such as delayed pregnancies, lifestyle disorders, and medical conditions like polycystic syndrome (PCOS) are fueling this trend. Government Support and Reimbursement Policies Many governments are introducing supportive policies and subsidies for fertility treatments, making them more accessible to the general population. Insurance coverage for ART procedures is also expanding in several countries. Rising Adoption of Personalized Medicine Personalized medicine, which involves tailoring treatments based on individual genetic profiles and health conditions, is becoming a key trend in ovarian hyperstimulation. This approach improves treatment outcomes and minimizes side effects. Growing Medical Tourism Countries like India, Thailand, and Mexico are becoming popular medical tourism destinations for fertility treatments due to their affordable yet high-quality services. This trend is expected to drive the demand for ovarian hyperstimulation treatments. Increasing Awareness and Education Campaigns and initiatives to educate individuals about infertility and available treatments are boosting the market. Increased awareness encourages early diagnosis and timely intervention, enhancing the success rates of ovarian hyperstimulation procedures. Challenges Despite its promising growth, the market faces certain challenges. High treatment costs remain a significant barrier for many individuals, particularly in low- and middle-income countries. Additionally, the risk of complications such as OHSS and the emotional and physical toll of fertility treatments may deter some patients. Efforts to address these challenges are crucial for sustained market growth. Demand Forecast by 2030 The demand for ovarian hyperstimulation treatments is expected to rise significantly by 2030. Factors such as improved accessibility, technological advancements, and a growing awareness of infertility treatments will drive this demand. Emerging markets in Asia-Pacific, Latin America, and the Middle East are likely to contribute substantially, driven by improving healthcare infrastructure and rising disposable incomes. Moreover, the increasing acceptance of ART among same-sex couples and single parents will further fuel the market. The integration of artificial intelligence and machine learning in treatment protocols is expected to enhance success rates and patient satisfaction, bolstering demand. Browse Trending Reports: https://aimarketresearch2024.blogspot.com/2024/12/remote-patient-care-market-size-share.html https://aimarketresearch2024.blogspot.com/2024/12/openstack-service-market-size-share.html https://aimarketresearch2024.blogspot.com/2024/12/gas-mixture-market-size-share-trends.html https://aimarketresearch2024.blogspot.com/2024/12/omega-3-pufa-market-size-share-trends.html Conclusion The ovarian hyperstimulation treatment market is poised for substantial growth in the coming years, driven by rising infertility rates, technological advancements, and growing awareness about ART. While challenges such as high costs and potential complications persist, efforts to address these issues are underway. By 2030, the market is expected to witness remarkable expansion, with significant contributions from emerging economies and advancements in personalized medicine. As the healthcare sector continues to evolve, the ovarian hyperstimulation treatment market will remain a vital component of reproductive health services. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email: corporatesales@databridgemarketresearch.com" This release was published on openPR.PHILADELPHIA and NEW YORK , Dec. 27, 2024 /PRNewswire/ -- FS KKR Capital Corp. (NYSE: FSK) today announced that it has completed its previously announced offering of an additional $100 million in aggregate principal amount of its 6.125% notes due 2030 (the "Notes"). The Notes will be a further issuance of, and form a single series with, the $600 million aggregate principal amount of 6.125% Notes due 2030 that FSK issued on November 20, 2024 , increasing the outstanding aggregate principal amount of the series to $700 million . BofA Securities, Inc., BMO Capital Markets Corp., J.P. Morgan Securities LLC, KKR Capital Markets LLC, SMBC Nikko Securities America, Inc., and Truist Securities, Inc. are acting as joint book-running managers for this offering. FSK intends to use the net proceeds of this offering for general corporate purposes, including potentially repaying outstanding indebtedness under credit facilities and certain notes. This announcement does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes, nor shall there be any offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. About FS KKR Capital Corp. FSK is a leading publicly traded business development company (BDC) focused on providing customized credit solutions to private middle market U.S. companies. FSK seeks to invest primarily in the senior secured debt and, to a lesser extent, the subordinated debt of private middle market companies. FSK is advised by FS/KKR Advisor, LLC. About FS/KKR Advisor, LLC FS/KKR Advisor, LLC (FS/KKR) is a partnership between FS Investments and KKR Credit that serves as the investment adviser to FSK and other business development companies. FS Investments is a global alternative asset manager dedicated to delivering superior performance and innovative investment and capital solutions. The firm manages over $83 billion in assets for a wide range of clients, including institutional investors, financial professionals and individual investors. FS Investments provides access to a broad suite of alternative asset classes and strategies through its best-in-class investment teams and partners. With its diversified platform and flexible capital solutions, the firm is a valued partner to general partners, asset owners and portfolio companies. FS Investments is grounded in its high-performance culture and guided by its commitment to building value for its clients, investing in its colleagues and giving back to its communities. The firm has more than 500 employees across offices in the U.S., Europe and Asia and is headquartered in Philadelphia . KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. Forward-Looking Statements and Important Disclosure Notice This announcement may contain certain forward-looking statements, including statements with regard to future events or future performance or operations of FSK. Words such as "believes," "expects," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include changes in the economy, risks associated with possible disruption in FSK's operations or the economy generally due to terrorism, geo-political risks, natural disasters or pandemics such as COVID-19, future changes in laws or regulations and conditions in FSK's operating area and the price at which shares of FSK's common stock trade on the New York Stock Exchange. Some of these factors are enumerated in the filings FSK makes with the SEC. FSK undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information: Investor Relations Contact Anna Kleinhenn Anna.Kleinhenn@fsinvestments.com FS Investments Media Team Melanie Hemmert Melanie.Hemmert@fsinvestments.com View original content to download multimedia: https://www.prnewswire.com/news-releases/fsk-completes-public-offering-of-100-million-6-125-unsecured-notes-due-2030--302339667.html SOURCE FS Investments

Arizona State dominates in Texas, giving CFP-seeking Big 12 exactly what it needsGlobal Portable Emergency Shelter Market Set For 2.4% Growth, Reaching $1.06 Billion By 2028

US agencies should use advanced technology to identify mysterious drones, Schumer says

‘Changes in foreign policy needed amid changing landscape,’ says Jaishankar

Lea en español For many people, this time of year is all about the shopping. And there's a fair chance many feel less than joyful about the prospect. If fulfilling your lengthy list feels overwhelming, learning what brain science and evolutionary psychology say about shopping and gift-giving might help you understand exactly why you're stressed – and even point you toward a healthier, happier holiday season. Our reactions are encoded into our nervous system, said Dr. Beth Frates, a part-time associate professor in the department of physical medicine and rehabilitation at Harvard Medical School in Boston. "By understanding these brain responses, people can develop strategies to manage stress better, such as setting realistic expectations, focusing on mindfulness and simplifying holiday preparations," said Frates, who also is the immediate past president of the American College of Lifestyle Medicine. The idea of exchanging gifts at this time of year can be traced back to pagan solstice celebrations. But the drive to share with another is as old as humanity itself, said Dr. Diego Guevara Beltran, a postdoctoral fellow in psychology at the University of Arizona in Tucson who studies cooperation and generosity. The science of generosity is more about survival than stocking stuffers, Guevara Beltran said. Sharing food gave early humans an evolutionary advantage. "Generosity is just one of the ways by which we can accumulate resources, be it wealth itself or friendships or work partners or more attractive, more intelligent mates," he said. Sharing with other people, Guevara Beltran said, is "a signal that communicates how much you value them, their welfare, your relationship with them." Research has shown that helping people makes us feel good. Part of that, he said, is because when someone is part of a community, they feel protected. One way this manifests is through the act of giving gifts. But to derive happiness from gift-giving, the giver needs to feel both that it was not an obligation and that it was effective, according to the 2019 World Happiness Report . That means it could be stressful to be in a culture where gift-giving feels mandatory, or if we can't see that a gift helped someone, Guevara Beltran speculated. It also might be stressful if gift-giving becomes a competition to show that you care about somebody more than the others around them. Our brains on shopping Stressful shopping can cause several physiological responses to kick in, Frates said. First is the "fight or flight" reaction that comes with stress. The release of chemicals that increase our heart rate, raise our blood pressure and intensify our breathing evolved to give us bursts of energy to escape danger. Frates said that while holiday stressors are not life-threatening, they can still trigger the stress response. The pressure to stay within budget could create a sense of scarcity, she said. "This taps into an evolutionary response, where the fear of losing resources like money can feel urgent and distressing." The holiday season also involves a lot of choices. "The brain has limited capacity for decision-making, and making multiple decisions can lead to decision fatigue," Frates said. "This fatigue reduces the ability to self-regulate and cope, which can lead to heightened stress responses when confronted with even minor setbacks, like a long line or out-of-stock item." The stress of needing to complete tasks within a limited time can intensify the fight-or-flight response, she said, as the brain interprets the ticking clock as a sense of urgency or threat. Meanwhile, Frates said, holiday shopping can also trigger brain chemicals that affect our feelings. "Dopamine, a neurotransmitter associated with pleasure and reward, is released when we anticipate something exciting or enjoyable, like finding a great gift or finding a good deal," she said. "This anticipation can feel rewarding even before any actual purchase is made." For some people, this dopamine boost can make shopping a relaxing experience. "It provides a temporary distraction from other stressors and allows them to focus on something positive, creating a 'holiday high,'" Frates said. For some people, that can be problematic. "When shopping becomes a way to chase that next dopamine hit, it can lead to excessive spending or impulsive purchases," she said. "This can become a trap, particularly during the holidays, when deals, sales and gift-giving pressures are everywhere." Understanding how all these processes work can help people recognize why they feel the way they do and adopt strategies to cope, Frates said. Here are some of her suggestions. 1. Start with self-care before shopping Prioritizing self-care means people can be their best selves and make good decisions, Frates said. So, "eat food that is delicious and nutritious. Get seven to nine hours of sleep. Make sure to enjoy physical activity. Take walks when you can and invite friends along. Practice stress reduction like meditation or yoga to help you calm your body and mind." Before going shopping, try taking deep breaths using stress-relieving techniques such as 4-7-8 breathing (inhale through your nose for four counts, hold for seven counts, and exhale through your mouth for eight) or box breathing (inhale through the nose for four counts, hold your breath for four, exhale for four, then hold for four). 2. Be strategic Don't shop when you're hungry, tired, lonely or stressed, Frates said. And don't start shopping 15 minutes before a store closes or a website's online deals end, she said. That's setting yourself up for triggering the fight-or-flight response. 3. Be mindful Before making a purchase, take a moment to consider whether it's truly needed or whether it's an impulsive choice. To avoid overindulging, set a specific budget or limit yourself to a couple of hours or specific shopping days. "This keeps dopamine-driven spending in check while still allowing for the enjoyable aspects of holiday shopping," Frates said. Look for post-shopping activities that provide rewards without the financial cost. That can satisfy your brain's desire for more dopamine in a healthier way. "Plan enjoyable, stress-relieving activities after shopping, like going for a walk, spending time with friends or indulging in a hobby," she said. 4. Bring a friend Not only does this support healthy social connections, Frates said, but if things start feeling stressful, "you have a buddy, and you have a support system right there for you." 5. Rethink the focus of the season "With gift-giving, we need to change mindsets in order to be able to manage the stress," Frates said. The holidays could be used to emphasize social connections, she said. "Thinking about the connection with the person and making gift-giving more about deepening the connection than anything else, I think, will really help to reduce the stress around the process," she said. So instead of scouring shops and websites for the "perfect" gift, think about making a meaningful and personal one, she suggested. It could be a poem, a painting, a song or a framed photograph that captured a special time. 6. Lessons for children It's easy to get caught up in the hunt for a hard-to-get item, Frates said. But ask yourself what the holiday means in your family's traditions. "Is it about getting that perfect gift for the child? Or is it about celebrating the meaning of that holiday?" So instead of having children ask for one specific toy, or a specific brand of clothing, teach them to leave a little leeway on their lists. "It is a good reminder to express to children that this season is about giving and sharing what we can in the best way that we can," she said, "and sometimes the exact gift is not available." Encouraging such an attitude can be a tall order, Frates said, but it's a place to start. "A simple mindset shift could be the difference between a stressful holiday shopping season or a joyful journey to find meaningful gifts for people you care about." American Heart Association News covers heart and brain health. Not all views expressed in this story reflect the official position of the American Heart Association. Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. Sign up here to get the latest health & fitness updates in your inbox every week!FSK Completes Public Offering of $100 million 6.125% Unsecured Notes Due 2030Where to Watch Wofford vs. South Carolina on TV or Streaming Live – Nov. 23

After weeks of fear and bewilderment about the drones buzzing over parts of New York and New Jersey , U.S. Senator Chuck Schumer is urging the federal government to deploy better drone-tracking technology to identify and ultimately stop the airborne pests. The New York Democrat is calling on the Department of Homeland Security to immediately deploy special technology that identifies and tracks drones back to their landing spots, according to briefings from his office. Recommended Videos Schumer’s calls come amid growing public concern that the federal government hasn’t offered clear explanations as to who is operating the drones, and has not stopped them. National security officials have said the drones don’t appear to be a sign of foreign interference. “There’s a lot of us who are pretty frustrated right now,” said Rep. Jim Himes, D-Conn., the top Democrat on the House Intelligence Committee, on Fox News Sunday. “The answer ‘We don’t know’ is not a good enough answer.” President-elect Donald Trump posted on social media last week: “Can this really be happening without our government’s knowledge? I don’t think so. Let the public know, and now. Otherwise, shoot them down.” Certain agencies within the Department of Homeland Security have the power to “incapacitate” drones, U.S. Secretary of Homeland Security Alejandro Mayorkas told ABC’s George Stephanopoulos on Sunday. “But we need those authorities expanded,” he said, without saying exactly how. The drones don’t appear to be linked to foreign governments, Mayorkas said. “We know of no foreign involvement with respect to the sightings in the Northeast. And we are vigilant in investigating this matter,” Mayorkas said. Last year, federal aviation rules began requiring certain drones to broadcast their identities. It’s not clear whether that information has been used to determine who is operating the drones swarming locations in New York and New Jersey. Mayorkas’ office didn’t immediately respond to questions about whether they’ve been able to identify drones using this capability. Schumer is calling for recently declassified radar technology to be used to help determine whether an object is a drone or a bird, identify its electronic registration, and follow it back to its landing place. New York Gov. Kathy Hochul on Sunday said federal officials were sending a drone detection system to the state. “This system will support state and federal law enforcement in their investigations,” Hochul said in a statement. The governor did not immediately provide additional details, including where the system will be deployed. Dozens of mysterious nighttime flights started last month over New Jersey, raising concerns among residents and officials. Part of the worry stems from the flying objects initially being spotted near the Picatinny Arsenal, a U.S. military research and manufacturing facility and over Trump’s golf course in Bedminster. Drones are legal in New Jersey for recreational and commercial use, but they are subject to local and Federal Aviation Administration regulations and flight restrictions. Operators must be FAA certified.

OpenAI Launches ChatGPT Pro for $200 a Month

Losing to older brother John Harbaugh and seeing the Los Angeles Chargers' four-game winning streak snapped Monday night might be the least of Jim Harbaugh's problems this week. The Chargers are holding their breath that running back J.K. Dobbins isn't seriously hurt after he left with a knee injury late in the first half of the Chargers’ 30-23 loss to the Baltimore Ravens . Harbaugh, who dislikes discussing injuries and eschews questions about any player's status with the tried and true “I'm not a doctor” answer, will get plenty of inquiries about Dobbins' health this week. After injuries derailed Dobbins' four years with the Ravens, the 2020 second-round pick decided to bet on himself by signing only a one-year deal with the Chargers. Though the first 10 1/2 games, the bet appeared to be paying off. Dobbins had 40 yards on six carries when he was wrenched backward by linebacker Malik Harrison and then gang-tackled on a play for no gain on third-and-1 at the 50-yard line. Dobbins is fourth in the AFC in rushing with 766 yards and averages 4.8 yards per carry, third highest among AFC backs with at least 100 carries. He has been considered among the candidates for AP Comeback Player of the Year after suffering a torn Achilles tendon in last season’s opener. Dobbins' production throughout the season has made the offense more balanced. Los Angeles had 14 rushes for 68 yards before he was injured. They had seven carries for 15 yards the rest of the game. Without Dobbins and a 14-13 deficit at halftime, the Chargers tried to count on Justin Herbert and the passing game to rally back. Herbert was 11 for 22 for 125 yards and sacked three times in the five drives after Dobbins' departure and didn't get back into the end zone until Gus Edwards' 1-yard run with 46 seconds remaining. Edwards will be counted on to be the lead back if Dobbins has to miss games. Edwards missed four games during the middle of the season because of an ankle injury and has 25 carries for 93 yards in three games since returning to the lineup. Hassan Haskins and rookie Kimani Vidal will be counted on to provide depth. “Obviously, I’m hoping J.K. is OK. Gus has been an awesome addition, being able to run and go and get some yards,” Herbert said. "We just got to stay with it. I think that offensive line has done a great job all year. It didn’t go our way today, but we’re going to keep pounding the ball and keep getting after it.” Dobbins' injury also could not come at a worse time for the Chargers. They are 7-4 and hold the sixth seed in the AFC, but have tough upcoming tests against playoff contenders Atlanta, Tampa Bay and Denver the next three weeks. What’s working Herbert on the run. Herbert has at four scrambles of at least 12 yards in the past five games and got his second rushing touchdown of the season on the opening drive with a 5-yard carry up the middle. What needs help Not giving up big-play touchdowns. Rashod Bateman's 40-yard touchdown late in the second quarter (which would have been pass interference on Kristian Fulton if it wasn't completed) marked the third straight game the Chargers allowed a passing TD of at least 40 yards. They had allowed only two in the first nine games. Stock up LB Joey Bosa had four tackles, his most since he had seven in Week 1 against the Raiders. Bosa missed three games earlier in the season because of a hip injury, but had only two tackles in the four games since his return until Monday night. Stock down WR Quentin Johnston is the second Chargers receiver since 2009 to be targeted at least five times and not have a catch according to Sportradar. Travis Benjamin also had five targets and no receptions against the Jets in 2017. Besides being held without a catch, Johnston had two critical drops during the second half. Injuries In addition to Dobbins, CB Eli Apple suffered a hamstring injury in the first half and did not return. CB Cam Hart was inactive because of an ankle injury and was in a walking boot. LB Denzel Perryman (groin) and TE Hayden Hurst (hip) were also inactive because of injuries. Key numbers 57 — Points allowed by the Chargers in the past two games. They had given up 68 in their first five games after their bye week. 73 — Games it took for Herbert to reach 1,800 completions, tying him with Kansas City's Patrick Mahomes as the fastest players in NFL history to reach that mark. 6 — Games where Daiyan Henley has had double-digit tackles. The second-year linebacker had 10 tackles (four solo) on Monday night. What’s next The Chargers will make their second trip in three years to Atlanta on Sunday. They won the 2022 meeting in Week 9 when Cameron Dicker hit a 37-yard field goal on the last play of the game. Los Angeles is 2-0 against the NFC South this season and has a four-game winning streak against teams in the division. ___ AP NFL: https://apnews.com/hub/NFL Joe Reedy, The Associated Press

AP Business SummaryBrief at 4:06 p.m. EST